Medicilon was selected as “2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise”
On September 27, the “STAR Summit” was grandly held in Shanghai. The Summit announced the selection list for the fourth anniversary of science and technology innovation.
Shanghai Medicilon Inc (Medicilon) has been selected as a ” 2023 Science and Technology Innovation Board Hard and Core Technology Leading Enterprise” based on its hard-core advantages in biopharmaceutical technology innovation over the years.
Technological innovation is the key to winning the future, and it is also what Medicilon is committed to pursuing. Over the past 19 years, Medicilon has continued to increase investment in research and development, focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA vaccines, PROTAC, ADC, bi/multi-specific antibodies and established an innovative service platform to help promote the “hard core” of drugs. In order to deepen the collaboration between the industry, academia and research institutions, Medicilon also established Medicilon Academician Innovation and Maturity Center, successfully signed the school-enterprise strategic collaboration with China Pharmaceutical University, and reached strategic collaboration with AI pharmaceutical companies such as Insilico Medicine and MindRank to assist the “hard-core” transformation of scientific and technological achievements. In addition, Medicilon also strengthened the construction of scientific and technological innovation talent teams, deepen the reform of talent development systems and mechanisms, support young people to take up the leading role in scientific and technological innovation, and help the “hard-core” growth of talents.
